The Latest Breaking News on Pharma

Another bivalent COVID-19 vaccine will be available to eligible Australians as a third and fourth booster, as case numbers climb.

Despite a spike in COVID-19 cases, the country's leading vaccine advisory body says Australians don't yet need a fifth dose of vaccine.

Gilead Sciences’ (GILD) popular covid product Veklury (Remdisivir) witnessed declining sales in the post-pandemic era. However, the company’s top line, excluding Veklury, has seen steady growth. Moreover, despite ongoing market volatility, the stock has registered stable gains. So, let’s find out if GILD is still a buy in the post-covid…

It was one of the first CBD companies in the UK almost 10 years ago

U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session.

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), released financial results for the third quarter ended September 30, 2022. Q3 2022 Financial Highlights

Swiss pharmaceutical firm carried out two identical phase 3 trials of gantenerumab, with about 1,000 volunteers in each

The company has deals with Asda, Boots, Holland & Barrett, Sainsbury’s, Tesco, the Co-op and Waitrose

Pharmacists can also administer a further six vaccines as of Monday.